EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access

Real-World Implementation and Evaluation of a Digital Health Platform for Children Living With Type 1 Diabetes: Protocol for a Real-World Implementation Study

Reale Implementierung und Evaluation einer digitalen Gesundheitsplattform für Kinder mit Typ-1-Diabetes: Protokoll einer Real-World-Implementierungsstudie

Shruti Muralidharan, Molly Sweeney Magee, Kimberly Charbonneau, Simona McKee, Carlie Zachariuk, Sukhpreet K Tamana, Gonzalo Dominguez-Menendez, Tricia S Tang, Elizabeth M Borycki, Andre W Kushniruk, Wyeth W Wasserman, Jeffrey N Bone und 2 weitere

JMIR Research Protocols · 30.10.2026 · 15 · e107634-e107634

DOI: 10.2196/107634 ↗

Auf einen Blick

Die Studie prüft die klinische Wirksamkeit und Implementierung von Haibu Diabetes in der pädiatrischen Routineversorgung bei Typ-1-Diabetes. Es handelt sich um ein Protokoll; Ergebnisse liegen noch nicht vor.

Fragestellung

Wie wirken sich Nutzung und Implementierung von Haibu Diabetes in der Routineversorgung von Kindern und Jugendlichen mit Typ-1-Diabetes auf klinische und Implementierungsoutcomes aus?

Methode

Nicht randomisierte, quasi-experimentelle, Typ-2-Hybridstudie an einem Krankenhaus; Jugendliche von 3 bis unter 18 Jahren mit T1D und Bezugspersonen, Vergleich mit gematchter Kontrollgruppe aus dem BC Pediatric Diabetes Registry.

Ergebnisse

Studienfinanzierung begann im Januar 2023. Rekrutierung startete im September 2026; bis Oktober 2026 hatten 7 Teilnehmende zugestimmt. Datenerhebung soll bis Dezember 2027 abgeschlossen sein.

Schlussfolgerung der Autor:innen

Die Studie soll Real-World-Evidenz zur Wirksamkeit und zu den Bedingungen für Implementierung und nachhaltige Nutzung einer datenintegrierenden digitalen Plattform in der pädiatrischen T1D-Versorgung liefern.

Kernaussagen

  • Protokoll einer nicht randomisierten Typ-2-Hybridstudie
  • Vergleich mit gematchter Kontrollgruppe aus dem Register
  • Ergebnisse zu Wirksamkeit und Implementierung stehen noch aus

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Studienprotokoll in der Zeitschrift JMIR Research Protocols, online erschienen am 30.10.2026. Verfasst von Shruti Muralidharan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Digital platforms that integrate continuous glucose monitoring, patient-generated data, and clinical decision support could enable more proactive pediatric type 1 diabetes (T1D) care. Sustained uptake of digital platforms in routine practice is limited, and the evidence of effectiveness is mixed. Implementation science approaches are needed to clarify how context, workflows, and strategies shape adoption and outcomes. Haibu Diabetes is a new platform that brings together wearable, patient-reported, and clinical diabetes data to generate personalized, data-driven insights for patients and clinicians.

Objective

This study evaluates the clinical effectiveness and implementation processes of Haibu Diabetes in routine pediatric T1D care using a hybrid design guided by an Implementation Research Logic Model.

Methods

We will conduct a nonrandomized, quasi-experimental, type 2 hybrid implementation-effectiveness trial at a hospital that provides multidisciplinary pediatric diabetes care. Youth aged 3 to less than 18 years with T1D and caregivers will be onboarded to Haibu Diabetes as part of routine workflows; health care providers will use a clinician dashboard to review data, assign tasks/forms, and communicate asynchronously. Effectiveness analyses will compare Haibu Diabetes users to a matched control group drawn from the BC Pediatric Diabetes Registry. Effectiveness outcomes are hemoglobin A 1c , continuous glucose monitoring device-derived time in range over 12 months, and diabetes self-care behaviors. Implementation outcomes will be assessed using mixed methods guided by an Implementation Research Logic Model that links determinants, implementation strategies, mechanisms, and outcomes. These outcomes will include reach, adoption, feasibility, acceptability, and maintenance. Health care improvement outcomes will include patient and caregiver experience, clinician experience, and operational workflow indicators.

Results

Study funding commenced in January 2023. Patient recruitment began in September 2026, and 7 participants had consented as of October 2026. Data collection is anticipated to conclude by December 2027, with analysis to follow. Study findings are expected to be published in summer 2028.

Conclusions

This trial will generate real-world evidence on both effectiveness and the conditions required to implement and sustain a data-integrating digital platform in pediatric T1D care, informing scale-up and optimization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1HumansChildDigital HealthAdolescentChild, PreschoolContinuous Glucose MonitoringFemaleMaleImplementation ScienceGlycated Hemoglobin

Stichwörter der Autor:innen

clinical workflowcontinuous glucose monitoringdigital healtheffectiveness-implementation hybrid trialimplementation sciencepatient-centered carepediatric diabetesreal-world evaluationtype 1 diabetes

Substanzen

Glycated Hemoglobin

Autor:innen und Institutionen

  • Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada.
  • BC Children's Hospital Research Institute, A4-196 938 West 28th Avenue, Vancouver, BC, V5Z 4H4, Canada.
  • Haibu Health, Vancouver, BC, Canada.
  • Department of Clinical Health Psychology, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada.
  • School of Health Information Science, University of Victoria, Victoria, BC, Canada.
  • Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.

Zitieren

APA

Muralidharan, S., Sweeney Magee, M., Charbonneau, K., McKee, S., Zachariuk, C., Tamana, S. K., Dominguez-Menendez, G., Tang, T. S., Borycki, E. M., Kushniruk, A. W., Wasserman, W. W., Bone, J. N., Görges, M., & Amed, S. (2026). Real-World Implementation and Evaluation of a Digital Health Platform for Children Living With Type 1 Diabetes: Protocol for a Real-World Implementation Study. JMIR Research Protocols, 15, e107634-e107634. https://doi.org/10.2196/107634

Vancouver

Muralidharan S, Sweeney Magee M, Charbonneau K, McKee S, Zachariuk C, Tamana SK, et al. Real-World Implementation and Evaluation of a Digital Health Platform for Children Living With Type 1 Diabetes: Protocol for a Real-World Implementation Study. JMIR Research Protocols. 2026;15:e107634-e107634. doi:10.2196/107634

BibTeX
@article{Muralidharan2026,
  author = {Muralidharan, Shruti and Sweeney Magee, Molly and Charbonneau, Kimberly and McKee, Simona and Zachariuk, Carlie and Tamana, Sukhpreet K and Dominguez-Menendez, Gonzalo and Tang, Tricia S and Borycki, Elizabeth M and Kushniruk, Andre W and Wasserman, Wyeth W and Bone, Jeffrey N and Görges, Matthias and Amed, Shazhan},
  title = {Real-World Implementation and Evaluation of a Digital Health Platform for Children Living With Type 1 Diabetes: Protocol for a Real-World Implementation Study},
  journal = {JMIR Research Protocols},
  year = {2026},
  volume = {15},
  pages = {e107634--e107634},
  doi = {10.2196/107634}
}
Kostenlos starten →